STUDY SUPPORTED BY RAKFOND WILL BE PRESENTED AT ASCO ANNUAL MEETING
Final results of the randomized phase II trial of olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy will be presented by its author Dr. Alexey Rumyantsev at the Annual Meeting of the American Society of Clinical Oncology (ASCO) as an oral presentation during the Symptoms and Survivorship session on June 3, 2019, in Chicago, USA. The session will be chaired by distinguished experts from leading cancer centers (Dana-Farber Cancer Institute and Duke University).
ASCO Annual Meeting is the largest scientific event in oncology, which gathers tens of thousands of oncologists from all over the world. Dr. Rumyantsev’s research has been selected for an oral presentation by the Scientific Program Committee from thousands of submitted abstracts. The study was carried out in the Department of Clinical Pharmacology and Chemotherapy of N.N. Blokhin National Medical Research Center of Oncology (Moscow, Russia). It was supported by the RUSSCO/RakFond’s Young Scientist & Early Career Investigator Oncology Research Grant.